PTPN2 restrains CD8+ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice

Journal of Autoimmunity

Volumn 53, Issue C, 2014, Pages 105-114

  Wiede, Florian ^a   Ziegler, Alexandra ^a   Zehn, Dietmar ^b   Tiganis, Tony ^a  

^a MONASH UNIVERSITY   (Australia)

^b Swiss Vaccine Research Institute   (Switzerland)

Author keywords

Autoimmunity; Cross presentation; Cytotoxic T lymphocyte; Immunity; PTPN2; Type 1 diabetes

Indexed keywords

B LYMPHOCYTE ANTIGEN; INTERLEUKIN 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; OVALBUMIN; T LYMPHOCYTE RECEPTOR; AUTOANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; PTPN2 PROTEIN, MOUSE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL DESTRUCTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DEHYDRATION; ENZYME ACTIVITY; FEMALE; GLUCOSE URINE LEVEL; GLUCOSURIA; HISTOLOGY; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTIGEN PRESENTATION; GENETICS; IMMUNOLOGY; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNE TOLERANCE; INSULIN-SECRETING CELLS; MICE; MICE, TRANSGENIC; NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION;

EID: 84926420809     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.05.008     Document Type: Article

References (59)

1. Klein L., Hinterberger M., Wirnsberger G., Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009, 9(12):833-844.
2. Kyewski B., Klein L. Acentral role for central tolerance. Annu Rev Immunol 2006, 24:571-606.
3. Zehn D., Bevan M.J. Tcells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006, 25(2):261-270.
4. Redmond W.L., Sherman L.A. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005, 22(3):275-284.
5. Kurts C., Carbone F.R., Barnden M., Blanas E., Allison J., Heath W.R., et al. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. JExp Med 1997, 186(12):2057-2062.
6. Belz G.T., Behrens G.M., Smith C.M., Miller J.F., Jones C., Lejon K., et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. JExp Med 2002, 196(8):1099-1104.
7. Kurts C., Heath W.R., Carbone F.R., Allison J., Miller J.F., Kosaka H. Constitutive class I-restricted exogenous presentation of self antigens invivo. JExp Med 1996, 184(3):923-930.
8. Kurts C., Heath W.R., Kosaka H., Miller J.F., Carbone F.R. The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). JExp Med 1998, 188(2):415-420.
9. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat Rev Immunol 2010, 10(6):403-414.
10. Luckashenak N., Schroeder S., Endt K., Schmidt D., Mahnke K., Bachmann M.F., et al. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance invivo. Immunity 2008, 28(4):521-532.
11. Bevan M.J. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during invivo priming. JImmunol 1976, 117(6):2233-2238.
12. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. JExp Med 1976, 143(5):1283-1288.
13. Ridge J.P., Di Rosa F., Matzinger P. Aconditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393(6684):474-478.
14. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393(6684):478-480.
15. Smith-Garvin J.E., Koretzky G.A., Jordan M.S. Tcell activation. Annu Rev Immunol 2009, 27:591-619.
16. Dustin M.L. The cellular context of T cell signaling. Immunity 2009, 30(4):482-492.
17. Palacios E.H., Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004, 23(48):7990-8000.
18. Stanford S.M., Rapini N., Bottini N. Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity. Immunology 2012, 137(1):1-19.
19. Rhee I., Veillette A. Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol 2012, 13(5):439-447.
20. Tiganis T., Bennett A.M. Protein tyrosine phosphatase function: the substrate perspective. Biochem J 2007, 402(1):1-15.
21. Tiganis T. PTP1B and TCPTP - nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J 2013, 280:445-458.
22. Festen E.A., Goyette P., Green T., Boucher G., Beauchamp C., Trynka G., et al. Ameta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet 2011, 7(1):e1001283.
23. Smyth D.J., Plagnol V., Walker N.M., Cooper J.D., Downes K., Yang J.H., et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. NEngl J Med 2008, 359(26):2767-2777.
24. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007, 39(7):857-864. [in eng].
25. WTCCC Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447(7145):661-678.
26. Espino-Paisan L., de la Calle H., Fernandez-Arquero M., Figueredo M.A., de la Concha E.G., Urcelay E., et al. Apolymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes. Immunogenetics 2011, 63(4):255-258.
27. Long S.A., Cerosaletti K., Wan J.Y., Ho J.C., Tatum M., Wei S., et al. An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells. Genes Immun 2011, 12:116-125.
28. Wiede F., Shields B.J., Chew S.H., Kyparissoudis K., van Vliet C., Galic S., et al. Tcell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. JClin Invest 2011, 121(12):4758-4774.
29. Zikherman J., Weiss A. Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease. JClin Invest 2011, 121(12):4618-4621.
30. Fukushima A., Loh K., Galic S., Fam B., Shields B., Wiede F., et al. T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis. Diabetes 2010, 59(8):1906-1914.
31. Loh K., Fukushima A., Zhang X., Galic S., Briggs D., Enriori P.J., et al. Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell Metab 2011, 14:684-699.
32. Wiede F.W., La Gruta N.L., Tiganis T. PTPN2 attenuates T cell lymphopenia-induced proliferation. Nat Commun 2013, 5:3073.
33. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 1994, 76(1):17-27.
34. Behrens G.M., Li M., Davey G.M., Allison J., Flavell R.A., Carbone F.R., et al. Helper requirements for generation of effector CTL to islet beta cell antigens. JImmunol 2004, 172(9):5420-5426.
35. Bennett S.R., Carbone F.R., Karamalis F., Miller J.F., Heath W.R. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. JExp Med 1997, 186(1):65-70.
36. Harbers S.O., Crocker A., Catalano G., D'Agati V., Jung S., Desai D.D., et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. JClin Invest 2007, 117(5):1361-1369.
37. Ge Q., Stone J.D., Thompson M.T., Cochran J.R., Rushe M., Eisen H.N., et al. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. Proc Natl Acad Sci U S A 2002, 99(21):13729-13734.
38. Hommel M., Hodgkin P.D. TCR affinity promotes CD8+ T cell expansion by regulating survival. JImmunol 2007, 179(4):2250-2260.
39. Pipkin M.E., Sacks J.A., Cruz-Guilloty F., Lichtenheld M.G., Bevan M.J., Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010, 32(1):79-90.
40. D'Souza W.N., Schluns K.S., Masopust D., Lefrancois L. Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. JImmunol 2002, 168(11):5566-5572.
41. Simoncic P.D., Lee-Loy A., Barber D.L., Tremblay M.L., McGlade C.J. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol 2002, 12(6):446-453.
42. Aoki N., Matsuda T. Anuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 2002, 16(1):58-69.
43. Malek T.R., Yu A., Scibelli P., Lichtenheld M.G., Codias E.K. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. JImmunol 2001, 166(3):1675-1683.
44. Imada K., Bloom E.T., Nakajima H., Horvath-Arcidiacono J.A., Udy G.B., Davey H.W., et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. JExp Med 1998, 188(11):2067-2074.
45. Enouz S., Carrie L., Merkler D., Bevan M.J., Zehn D. Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. JExp Med 2012, 209(10):1769-1779.
46. Schietinger A., Delrow J.J., Basom R.S., Blattman J.N., Greenberg P.D. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 2012, 335(6069):723-727.
47. Mueller D.L. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010, 11(1):21-27.
48. Schietinger A., Greenberg P.D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 2013, 35(2):51-60.
49. ten Hoeve J., Ibarra-Sanchez M.J., Fu Y., Zhu W., Tremblay M., David M., et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002, 22(16):5662-5668.
50. Yamamoto T., Sekine Y., Kashima K., Kubota A., Sato N., Aoki N., et al. The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. Biochem Biophys Res Commun 2002, 297(4):811-817.
51. Shields B.J., Wiede F., Gurzov E.N., Wee K., Hauser C., Zhu H.J., et al. TCPTP regulates SFK and STAT3 signalling and is lost in triple negative breast cancers. Mol Cell Biol 2013, 33(3):557-570.
52. Chang P.P., Lee S.K., Hu X., Davey G., Duan G., Cho J.H., et al. Breakdown in repression of IFN-gamma mRNA leads to accumulation of self-reactive effector CD8+ T cells. JImmunol 2012, 189(2):701-710.
53. Li Q.J., Chau J., Ebert P.J., Sylvester G., Min H., Liu G., et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007, 129(1):147-161.
54. Flinsenberg T.W., Compeer E.B., Boelens J.J., Boes M. Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin Exp Immunol 2011, 165(1):8-18.
55. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Lienard D., Lejeune F., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004, 64(8):2865-2873.
56. Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012, 72(4):887-896.
57. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363(8):711-723.
58. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N.Engl J Med 2012, 366(26):2443-2454.
59. Merry T.L., Tran M., Stathopoulos M., Wiede F., Fam B.C., Dodd G.T., et al. High fat fed obese Gpx1-deficient mice exhibit defective insulin secretion but protection from hepatic steatosis and liver damage. Antioxid Redox Signal 2013, 20(14):2114-2129.